Armata Pharmaceuticals Inc (ARMP) Stock Price, Quote & News

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 665 2928

Fax: 310 665 2963

Website: www.armatapharma.com

Address:

5005 McConnell Avenue, Los Angeles, United States

Trapped Dec. 24 at 8:55 PM

$ARMP 2026 will set things on the almighty list. buy em and hold em. future is set. easily reaching $50 in 2026.

0 · Reply

prallrichard Dec. 22 at 7:04 PM

$ARMP Momentum for ARMP is strongly bullish. The 14-period Slow Stochastic Oscillator is rising, as investors pay higher prices for shares.

0 · Reply

prallrichard Dec. 22 at 7:04 PM

$ARMP ARMP appears to be correcting within a longer-term bullish trend. Although its MACD is presently below the signal line, shares remain 115.1% above an upwards sloping 200-day moving average. Comparative Relative Strength analysis shows that this issue is outperforming the S&P 500.

0 · Reply

Paytient Dec. 19 at 11:37 PM

$ARMP did I miss some news? Why’d we jump today?

1 · Reply

SuperGreenToday Dec. 19 at 2:48 AM

$ARMP Share Price: $5.38 Contract Selected: May 15, 2026 $5 Calls Buy Zone: $2.03 – $2.50 Target Zone: $3.63 – $4.44 Potential Upside: 69% ROI Time to Expiration: 147 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Trapped Dec. 12 at 2:19 AM

$ARMP just bouncing around for no reason. phase 3 going to rock the house. $50

1 · Reply

SmartOptionsAlert Dec. 11 at 11:49 PM

📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $ARMP | Timeframe: 3M / 1H Market Cap: $210.07M • Pattern score: 0.73 • Current price: $5.950 • Peak (window): $11.760 • Trough (post-spike): $4.670 • Pullback: ~60.3% from peak • Move off lows: ~50.6% of peak Stock Plan (educational only) • Entry zone: $5.771 – $6.069 • Scalp target: $6.426 → Est. ROI: ~8.0% • Swing target: $9.408 → Est. ROI: ~58.1% • Protective stop: $5.057 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $MSTR

0 · Reply

SmartOptionsAlert Dec. 11 at 5:27 AM

📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $ARMP | Timeframe: 3M / 1H Market Cap: $206.43M • Pattern score: 0.73 • Current price: $5.890 • Peak (window): $11.760 • Trough (post-spike): $4.670 • Pullback: ~60.3% from peak • Move off lows: ~50.1% of peak Stock Plan (educational only) • Entry zone: $5.713 – $6.008 • Scalp target: $6.361 → Est. ROI: ~8.0% • Swing target: $9.408 → Est. ROI: ~59.7% • Protective stop: $5.006 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $QS

0 · Reply

SmartOptionsAlert Dec. 11 at 3:35 AM

0 · Reply

SmartOptionsAlert Dec. 11 at 1:53 AM

0 · Reply

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 10, 2025, 7:00 AM EST - 6 weeks ago

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Oct 22, 2025, 11:10 AM EDT - 2 months ago

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Oct 14, 2025, 7:00 AM EDT - 2 months ago

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Sep 8, 2025, 7:00 AM EDT - 3 months ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 4, 2025, 7:00 AM EDT - 3 months ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

May 19, 2025, 7:00 AM EDT - 7 months ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 14, 2025, 4:05 PM EDT - 8 months ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 1, 2025, 7:00 AM EDT - 8 months ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Mar 20, 2025, 5:56 PM EDT - 9 months ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 10 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

INVA

Mar 11, 2025, 7:00 AM EDT - 10 months ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Dec 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 13, 2024, 4:05 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Structural Biology Publication

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 10, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

May 7, 2024, 4:01 PM EDT - 1 year ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 4, 2024, 4:01 PM EST - 1 year ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

INVA

Feb 21, 2024, 7:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Nov 14, 2023, 4:00 PM EST - 2 years ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

May 31, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 11, 2023, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 6, 2023, 6:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Jan 10, 2023, 4:05 PM EST - 3 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

INVA

Dec 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 28, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 9, 2022, 4:15 PM EST - 3 years ago

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

May 23, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

May 12, 2022, 4:17 PM EDT - 3 years ago

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

Mar 31, 2022, 4:05 PM EDT - 4 years ago

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

INVA

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

Trapped Dec. 24 at 8:55 PM

$ARMP 2026 will set things on the almighty list. buy em and hold em. future is set. easily reaching $50 in 2026.

0 · Reply

prallrichard Dec. 22 at 7:04 PM

$ARMP Momentum for ARMP is strongly bullish. The 14-period Slow Stochastic Oscillator is rising, as investors pay higher prices for shares.

0 · Reply

prallrichard Dec. 22 at 7:04 PM

0 · Reply

Paytient Dec. 19 at 11:37 PM

$ARMP did I miss some news? Why’d we jump today?

1 · Reply

SuperGreenToday Dec. 19 at 2:48 AM

0 · Reply

Trapped Dec. 12 at 2:19 AM

$ARMP just bouncing around for no reason. phase 3 going to rock the house. $50

1 · Reply

SmartOptionsAlert Dec. 11 at 11:49 PM

0 · Reply

SmartOptionsAlert Dec. 11 at 5:27 AM

0 · Reply

SmartOptionsAlert Dec. 11 at 3:35 AM

0 · Reply

SmartOptionsAlert Dec. 11 at 1:53 AM

0 · Reply

SmartOptionsAlert Dec. 11 at 12:06 AM

0 · Reply

History101 Dec. 10 at 3:53 PM

$ARMP down over 10%, SSRs in effect rest of day today, all day tomorrow...GLTALs!!

0 · Reply

prallrichard Dec. 10 at 2:32 PM

$ARMP https://www.armatapharma.com/

0 · Reply

prallrichard Dec. 9 at 11:46 PM

$ARMP Weird stuff going on when I check positions ARMP shows .83 down!

0 · Reply

prallrichard Dec. 9 at 11:43 PM

$ARMP Was there a halt?

0 · Reply

SailingCrab Dec. 9 at 7:21 PM

$ARMP Schwab is rejecting my buy order saying this order can not be placed electronically. I already have some and am just trying to add more, is something going on today that I don’t know about?

3 · Reply

prallrichard Dec. 9 at 6:47 PM

$ARMP 3rd Resistance Point 6.15 2nd Resistance Point 6.02 1st Resistance Point 5.76 Last Price 5.87 1st Support Level 5.36 2nd Support Level 5.23 3rd Support Level 4.97

0 · Reply

prallrichard Dec. 9 at 6:45 PM

$ARMP ARMP appears to be correcting within a longer-term bullish trend. Although its MACD is presently below the signal line, shares remain 104.7% above an upwards sloping 200-day moving average. Comparative Relative Strength analysis shows that this issue is outperforming the S&P 500.

0 · Reply

Kingcrab33333 Dec. 4 at 6:15 PM

$ARMP ( load)

0 · Reply

HexBinance Dec. 4 at 5:23 PM

$CLSK I have the self-awareness to understand that I'm probably most likely talking to no one other than myself here but if I gained any faith with $ARMP ( stay in there and put more in when you're comfortable) please let me Direct some of your attention over to $RCEL. I'm not a wizard I don't know the future, but I take my time and I only invest in things I have 100% concrete evidence of. Long term very valuable short-term it's a steal.

1 · Reply

HexBinance Dec. 3 at 10:22 PM

$CLSK $ARMP went from -20% EOD yesterday to +12% EOD today, and for you young whipper snappers that's called a Bullish Shakeout. It happens on smallcap rocketships as an attempt to shakeout you paper hands who still believe stop-losses are there to help you. Time to wake up, Hunnie, because the bad guys have been winning for too long. Same old story, weak hands were flushed out and the knowing swooped in and gobbled up free money. If it was a reversal it n wouldn't have snapped back with such strength today. The money is still in charge. I gave it to you without expecting anything in return simply because if you're on team Matt & Zach then I want us all to do well together.

2 · Reply

HexBinance Dec. 3 at 3:20 PM

$CLSK in case you guys thought I was just another one of these jerk off tights trying to steal your money let me remind you that I told you about $ARMP yesterday when it was down 20%

0 · Reply

Market Cap	228.64M
Revenue (ttm)	5.17M
Net Income (ttm)	-18.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-365.96%
Debt to Equity Ratio	-1.53

Volume	3,400
Avg Vol	355,424
Day's Range	N/A - N/A
Shares Out	36.41M
Stochastic %K	91%
Beta	1.24
Analysts	Sell
Price Target	$9.00